GJA1 and ischemia: Moreover, the release of EV-Cx43 in ischemia was not significantly disturbed by pre-treatment with the ubiquitination inhibitor Heclin, suggesting that ischemia-induced ubiquitination of Cx43 results in early commitment with degradation, even before a significant Cx43 decrease, ultimately restraining the release of EV-Cx43 (Fig S5K).